Innate Immunotherapeutics Ltd (IIL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Innate Immunotherapeutics Ltd (IIL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3295
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Innate Immunotherapeutics Ltd (Innate Immunotherapeutics), formerly Innate Therapeutics Ltd is a pharmaceutical company that develops therapeutic drugs for the treatment of cancer and infectious diseases. The company utilizes immunomodulator microparticle technology. It develops lead drug candidate MIS416 to treat patients with secondary progressive multiple sclerosis. The company uses microparticle platform technology that induces the human immune system to fight against various cancers and infections; and to design preventive vaccines for influenza, cancer, malaria, or tuberculosis. The company’s products find application in the treatment of pancreatic and ovarian cancer, and chronic diseases, such as idiopathic pulmonary fibrosis. It has presence in Australia and New Zealand. Innate Immunotherapeutics is headquartered in Melbourne, Victoria, Australia.

Innate Immunotherapeutics Ltd (IIL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 10
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 13
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 15
Innate Immunotherapeutics Raises US8.95 Million Public Offering Of Shares 16
Innate Immunotherapeutics Completes IPO For US$9 Million 17
Acquisition 19
Innate Immunotherapeutics Completes Acquisition of Amplia Therapeutics 19
Innate Immunotherapeutics Ltd – Key Competitors 20
Innate Immunotherapeutics Ltd – Key Employees 21
Innate Immunotherapeutics Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Jul 30, 2018: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report of the year 2018 23
Corporate Communications 24
May 28, 2018: Innate Immunotherapeutics Names Dr. Warwick Tong As Chairman 24
Legal and Regulatory 25
Aug 08, 2018: Congressman Christopher Collins And Others Charged In Manhattan Federal Court With Insider Trading And Lying To Federal Law Enforcement Agents 25
Other Significant Developments 28
Oct 30, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 28
Jul 28, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innate Immunotherapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 10
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 13
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 15
Innate Immunotherapeutics Raises US8.95 Million Public Offering Of Shares 16
Innate Immunotherapeutics Completes IPO For US$9 Million 17
Innate Immunotherapeutics Completes Acquisition of Amplia Therapeutics 19
Innate Immunotherapeutics Ltd, Key Competitors 20
Innate Immunotherapeutics Ltd, Key Employees 21
Innate Immunotherapeutics Ltd, Subsidiaries 22

List of Figures
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Innate Immunotherapeutics Ltd (IIL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Illumina Inc (ILMN):医療機器:M&Aディール及び事業提携情報
    Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company’s portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microar …
  • PharmAust Ltd (PAA):企業の財務・戦略的SWOT分析
    Summary PharmAust Ltd (PAA) is a clinical-stage company that focuses on the development of targeted cancer therapeutics for the treatment of human and veterinary cancers. The company’s lead product candidate Monepantel is a small molecule that has been developed to treat parasite infections in food …
  • Take-Two Interactive Software, Inc. (TTWO):企業の財務・戦略的SWOT分析
    Take-Two Interactive Software, Inc. (TTWO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Avacta Group Plc (AVCT):企業の製品パイプライン分析2018
    Summary Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products that include optim and sensipod. It also develops UCB celltech that is an analytical instrument. Avacta’s sensipod is an …
  • Smith & Nephew Plc (SN.)-製薬・医療分野:企業M&A・提携分析
    Summary Smith & Nephew Plc (Smith & Nephew) develops, manufactures and markets medical devices for use in orthopedic reconstruction, orthopedic trauma and clinical therapies, sports medicines and advanced wound management. The company offers its products in various categories including Sports Medici …
  • HearMeOut Ltd (HMO):企業の財務・戦略的SWOT分析
    HearMeOut Ltd (HMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Danfoss AS:企業の戦略的SWOT分析
    Danfoss AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • NGEx Resources Inc:企業のM&A・事業提携・投資動向
    NGEx Resources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NGEx Resources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Shop Direct Holdings Limited:企業の戦略・SWOT・財務情報
    Shop Direct Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Shop Direct Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • AIA Bhd:企業の戦略・SWOT・財務情報
    AIA Bhd - Strategy, SWOT and Corporate Finance Report Summary AIA Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Diversicare Healthcare Services Inc (DVCR):製薬・医療:M&Aディール及び事業提携情報
    Summary Diversicare Healthcare Services Inc (Diversicare), formerly Advocat Inc is a healthcare service provider that offers post acute care services and short term rehabilitation and long-term care services to nursing home patients. The company’s services include life steps rehabilitation program, …
  • Tom N Toms Holdings Co., Ltd.:企業の戦略・SWOT・財務情報
    Tom N Toms Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tom N Toms Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Ominto Inc (OMNT):企業の戦略的SWOT分析
    Ominto Inc (OMNT) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ROHA Dyechem Pvt. Ltd.:企業の戦略・SWOT・財務情報
    ROHA Dyechem Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report Summary ROHA Dyechem Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • PRA Health Sciences Inc (PRAH)-製薬・医療分野:企業M&A・提携分析
    Summary PRA Health Sciences Inc (PRA) is a contract research organization(CRO) which provides clinical development services. The company offers services such as phase I-IV study management, and embedded and functional outsourcing services. It offers solutions in bioanalytical laboratories, biometric …
  • Pfenex Inc (PFNX)-製薬・医療分野:企業M&A・提携分析
    Summary Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The company’s lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases. It also develops PF530, a biosimilar candidate for the treatment of multiple scl …
  • Sandoz Inc-製薬・医療分野:企業M&A・提携分析
    Summary Sandoz Inc (Sandoz), a division of Novartis AG, is a generic pharmaceutical company that develops, manufactures and distributes and sells a range of prescription medicines and protein and biotechnology-based products known as biosimilars. The company also provides intermediary products inclu …
  • Corcept Therapeutics Inc (CORT):企業の財務・戦略的SWOT分析
    Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Petrol dd Ljubljana (PETG):企業の財務・戦略的SWOT分析
    Petrol dd Ljubljana (PETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Korn/Ferry International:企業の戦略・SWOT・財務情報
    Korn/Ferry International - Strategy, SWOT and Corporate Finance Report Summary Korn/Ferry International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆